- |||||||||| Trial completion, Enrollment change, Trial completion date, Trial primary completion date: A Study of Flt3-Ligand Levels in Sjögrens Syndrome (clinicaltrials.gov) - Apr 24, 2019
P=N/A, N=30, Completed, Active, not recruiting --> Completed | Trial completion date: May 2019 --> Jul 2018 Recruiting --> Completed | N=50 --> 30 | Trial completion date: Dec 2019 --> Apr 2019 | Trial primary completion date: Dec 2019 --> Apr 2019
- |||||||||| Biomarker, Trial completion: Salivary Biomarkers for Sj (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=420, Completed, Recruiting --> Completed | N=50 --> 30 | Trial completion date: Dec 2019 --> Apr 2019 | Trial primary completion date: Dec 2019 --> Apr 2019 Active, not recruiting --> Completed
- |||||||||| Trial completion: NeuroSenSS: Primary Sj (clinicaltrials.gov) - Jan 11, 2019
P=N/A, N=44, Completed, N=18 --> 34 | Trial completion date: Dec 2018 --> May 2019 Recruiting --> Completed
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial completion, Surgery, Metastases: Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 20, 2018 P2, N=81, Completed, Recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| dexamethasone / Generic mfg.
Trial termination: Dexamethasone Irrigation of the Parotid Glands in Primary Sj (clinicaltrials.gov) - Nov 2, 2018 P2, N=14, Terminated, Active, not recruiting --> Completed | Trial completion date: Apr 2017 --> Jul 2017 Completed --> Terminated; Slow enrollment
- |||||||||| Trial completion: Multi-Colored Placido Disk Viability (clinicaltrials.gov) - Oct 5, 2018
P=N/A, N=16, Completed, Phase classification: P=N/A --> P2 Active, not recruiting --> Completed
- |||||||||| Trial completion, Enrollment change: Salivary Evaluation in Healthy Volunteers (clinicaltrials.gov) - Sep 24, 2018
P=N/A, N=173, Completed, Active, not recruiting --> Completed Recruiting --> Completed | N=250 --> 173
- |||||||||| Trial completion date, Trial primary completion date: A Study of Flt3-Ligand Levels in Sjögrens Syndrome (clinicaltrials.gov) - Aug 14, 2018
P=N/A, N=50, Recruiting, Active, not recruiting --> Completed Trial completion date: Dec 2017 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2019
- |||||||||| cisplatin / Generic mfg., docetaxel / Generic mfg., sorafenib / Generic mfg.
Trial completion, Combination therapy, Metastases: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jun 1, 2018 P1/2, N=3, Completed, Trial completion date: Dec 2017 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2019 Active, not recruiting --> Completed
- |||||||||| Phase classification: Salivary Evaluation in Healthy Volunteers (clinicaltrials.gov) - Mar 30, 2018
P, N=250, Recruiting, Trial completion date: Apr 2018 --> Dec 2018 Phase classification: P=N/A --> P
- |||||||||| prezalumab (AMG 557) / Amgen, AstraZeneca
Trial completion date, Trial primary completion date: A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sj (clinicaltrials.gov) - Mar 3, 2018 P2a, N=32, Active, not recruiting, Phase classification: P=N/A --> P Trial completion date: Aug 2018 --> Aug 2018 | Trial primary completion date: Feb 2018 --> Jan 2018
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial completion date, Metastases: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Feb 26, 2018 P2, N=24, Completed, Trial completion date: Aug 2018 --> Aug 2018 | Trial primary completion date: Feb 2018 --> Jan 2018 Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Oct 2017
- |||||||||| prezalumab (AMG 557) / Amgen, AstraZeneca
Enrollment closed, Enrollment change: A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sj (clinicaltrials.gov) - Nov 27, 2017 P2a, N=32, Active, not recruiting, Trial primary completion date: Nov 2018 --> Nov 2019 | Trial completion date: Nov 2018 --> Nov 2020 Recruiting --> Active, not recruiting | N=42 --> 32
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial primary completion date, Surgery, Metastases: Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 22, 2017 P2, N=79, Active, not recruiting, Recruiting --> Active, not recruiting | N=42 --> 32 Trial primary completion date: Dec 2017 --> May 2017
- |||||||||| Enrollment change, Trial withdrawal, Trial primary completion date: Examining the Immunological Process of Autoimmune Patients (clinicaltrials.gov) - Aug 8, 2017
P=N/A, N=0, Withdrawn, Trial primary completion date: Dec 2017 --> May 2017 N=200 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Jul 2017 --> Aug 2016
- |||||||||| Trial primary completion date: A Study of Flt3-Ligand Levels in Sjögrens Syndrome (clinicaltrials.gov) - Jul 5, 2017
P=N/A, N=50, Recruiting, Trial primary completion date: Jul 2017 --> Feb 2018 Trial primary completion date: Jun 2017 --> Dec 2017
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial primary completion date, Surgery, Metastases: Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Apr 25, 2017 P2, N=76, Active, not recruiting, Trial primary completion date: Nov 2017 --> Nov 2018 Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| cisplatin / Generic mfg., docetaxel / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Mar 3, 2017 P1/2, N=3, Active, not recruiting, Enrolling by invitation --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| Biomarker, Enrollment closed: Salivary Biomarkers for Sj (clinicaltrials.gov) - Feb 6, 2017
P=N/A, N=420, Active, not recruiting, Not yet recruiting --> Completed | Phase classification: P2 --> PN/A | Trial primary completion date: Mar 2015 --> Sep 2016 Enrolling by invitation --> Active, not recruiting
- |||||||||| prezalumab (AMG 557) / Amgen, AstraZeneca
Phase classification, Trial primary completion date: A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sj (clinicaltrials.gov) - Jan 11, 2017 P2a, N=42, Recruiting, Enrolling by invitation --> Active, not recruiting Phase classification: P2 --> P2a | Trial primary completion date: Feb 2017 --> Jul 2017
- |||||||||| carboplatin / Generic mfg., amifostine / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Metastases: Randomized Amifostine For SCCHN (clinicaltrials.gov) - Jan 4, 2017 P2, N=58, Completed, Trial primary completion date: Apr 2015 --> Oct 2014 Active, not recruiting --> Completed | N=90 --> 58 | Trial primary completion date: Jun 2009 --> Jun 2007
- |||||||||| Trial primary completion date: Multi-Colored Placido Disk Viability (clinicaltrials.gov) - Oct 3, 2016
P=N/A, N=20, Active, not recruiting, N=100 --> 13 | Recruiting --> Terminated | Trial primary completion date: Oct 2009 --> Mar 2011; poor recruitment Trial primary completion date: Sep 2016 --> Sep 2018
- |||||||||| gefitinib / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Metastases: Iressa Study in Patients With Salivary Gland Cancer (clinicaltrials.gov) - Sep 23, 2016 P2, N=37, Completed, No longer recruiting --> Completed Active, not recruiting --> Completed | N=80 --> 37 | Trial primary completion date: Nov 2017 --> Sep 2016
- |||||||||| Enrollment change, Trial termination, Trial primary completion date: Effects of Sustained Reading on the Ocular Surface (clinicaltrials.gov) - Aug 22, 2016
P=N/A, N=34, Terminated, Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Apr 2017 N=50 --> 34 | Suspended --> Terminated | Trial primary completion date: Dec 2016 --> Jun 2016; PI is moving to a different institution.
- |||||||||| Trial primary completion date: NeuroSenSS: Primary Sj (clinicaltrials.gov) - Aug 22, 2016
P=N/A, N=55, Recruiting, N=50 --> 34 | Suspended --> Terminated | Trial primary completion date: Dec 2016 --> Jun 2016; PI is moving to a different institution. Trial primary completion date: Sep 2015 --> Sep 2016
- |||||||||| Trial primary completion date: A Study of Flt3-Ligand Levels in Sjögrens Syndrome (clinicaltrials.gov) - Aug 10, 2016
P=N/A, N=50, Recruiting, Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Jun 2016 --> Jun 2017
|